Compile Data Set for Download or QSAR
Report error Found 52 Enz. Inhib. hit(s) with all data for entry = 11898
TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658503(US20240083904, Example 3.0)
Affinity DataKi:  0.160nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658499(US20240083904, Example 2.6)
Affinity DataKi:  0.170nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658501(US20240083904, Example 2.8)
Affinity DataKi:  0.190nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658502(US20240083904, Example 2.9)
Affinity DataKi:  0.200nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658498(US20240083904, Example 2.5)
Affinity DataKi:  0.320nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658500(US20240083904, Example 2.7)
Affinity DataKi:  0.340nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658496(US20240083904, Example 2.3)
Affinity DataKi:  0.460nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658495(US20240083904, Example 2.2)
Affinity DataKi:  0.5nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658504(2-(3-Cyanophenyl)-N-[(1S)-2-hydroxy-1,2-dimethyl-p...)
Affinity DataKi:  0.680nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658494(US20240083904, Example 2.1)
Affinity DataKi:  0.790nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658497(US20240083904, Example 2.4)
Affinity DataKi:  2.30nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658493(US20240083904, Example 2.0)
Affinity DataKi:  3.90nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2a(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658492(US20240083904, Example 1.0)
Affinity DataKi:  10.9nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658499(US20240083904, Example 2.6)
Affinity DataKi:  18nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658496(US20240083904, Example 2.3)
Affinity DataKi:  18nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658502(US20240083904, Example 2.9)
Affinity DataKi:  20nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658495(US20240083904, Example 2.2)
Affinity DataKi:  27nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658499(US20240083904, Example 2.6)
Affinity DataKi:  30nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658503(US20240083904, Example 3.0)
Affinity DataKi:  31nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658498(US20240083904, Example 2.5)
Affinity DataKi:  34nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658504(2-(3-Cyanophenyl)-N-[(1S)-2-hydroxy-1,2-dimethyl-p...)
Affinity DataKi:  49nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658503(US20240083904, Example 3.0)
Affinity DataKi:  71nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658498(US20240083904, Example 2.5)
Affinity DataKi:  78nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658500(US20240083904, Example 2.7)
Affinity DataKi:  79nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658496(US20240083904, Example 2.3)
Affinity DataKi:  95nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658502(US20240083904, Example 2.9)
Affinity DataKi:  96nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658504(2-(3-Cyanophenyl)-N-[(1S)-2-hydroxy-1,2-dimethyl-p...)
Affinity DataKi:  120nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658497(US20240083904, Example 2.4)
Affinity DataKi:  156nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658494(US20240083904, Example 2.1)
Affinity DataKi:  212nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658501(US20240083904, Example 2.8)
Affinity DataKi:  243nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658501(US20240083904, Example 2.8)
Affinity DataKi:  285nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658497(US20240083904, Example 2.4)
Affinity DataKi:  286nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658500(US20240083904, Example 2.7)
Affinity DataKi:  324nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658495(US20240083904, Example 2.2)
Affinity DataKi:  363nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658492(US20240083904, Example 1.0)
Affinity DataKi:  500nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A1(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658494(US20240083904, Example 2.1)
Affinity DataKi:  667nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658503(US20240083904, Example 3.0)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658502(US20240083904, Example 2.9)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658504(2-(3-Cyanophenyl)-N-[(1S)-2-hydroxy-1,2-dimethyl-p...)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658501(US20240083904, Example 2.8)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658500(US20240083904, Example 2.7)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658499(US20240083904, Example 2.6)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658498(US20240083904, Example 2.5)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658497(US20240083904, Example 2.4)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658496(US20240083904, Example 2.3)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658495(US20240083904, Example 2.2)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658494(US20240083904, Example 2.1)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658493(US20240083904, Example 2.0)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A3(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658492(US20240083904, Example 1.0)
Affinity DataKi: >1.00E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Adorx Therapeutics

US Patent
LigandPNGBDBM658493(US20240083904, Example 2.0)
Affinity DataKi:  1.58E+3nMAssay Description:All FRET binding experiments were conducted at room temperature in white 384-well plates, in assay binding buffer containing 1× LabMed (Cisbio, Franc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 52 total ) | Next | Last >>
Jump to: